TC
IOVA icon

Truvestments Capital’s Iovance Biotherapeutics IOVA Stock Holding History

Truvestments Capital’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.07K Buy
+1,460
New +$5.55K ﹤0.01% 865

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Truvestments Capital's IOVA Position: Q2 2026 in Review

Truvestments Capital opened a new position in Iovance Biotherapeutics (IOVA) in Q2 2026: 1,460 shares worth $6.07K. The stake represents ﹤0.01% of the portfolio and ranks #865 among its holdings.

292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Truvestments Capital held 1,460 shares of Iovance Biotherapeutics worth $6.07K as of Q2 2026.
  • Iovance Biotherapeutics was a new Truvestments Capital position in Q2 2026.
  • Iovance Biotherapeutics made up ﹤0.01% of Truvestments Capital's portfolio in Q2 2026, its #865 holding.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Truvestments Capital's 13F filing for Q2 2026, filed 12 Aug 2026.